Interestingly, studies revealed that sorafenib could decrease the expression of SIRT3, which contributes to its reduced drug sensitivity, while up-regulation of SIRT3 can re-sensitize HCC to sorafenib treatment 102-104. Here, SIRT3 is linked to hepatocellular carcinoma.